Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on August 14, 2026, and is payable October 7, 2026, to shareholders of record at the close of business on September 21, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned here…

Results of Operations and Financial Condition. On August 4, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference…

Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on July 30, 2026, and is payable September 1, 2026, to shareholders of record at the close of business on August 15, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be sig…

Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on May 14, 2026, and is payable July 7, 2026, to shareholders of record at the close of business on June 22, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly a…

Results of Operations and Financial Condition. On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…

Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on April 28, 2026, and is payable June 1, 2026, to shareholders of record at the close of business on May 15, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on…

President of Bruker BioSpin Group and Executive Officer — Falko Busse, Ph.D.: Dr. Busse's employment with the Company and Bruker BioSpin will terminate as of October 31, 2026.

Director — Thierry L. Bernard: Appointment of Thierry L. Bernard as a new director to expand the Board size.

Director — Dr. Cynthia M. Friend: Dr. Cynthia M. Friend retired from the Board of Directors, and Jack Phillips was re-elected as a Class II director.

Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on February 19, 2026, and is payable April 7, 2026, to shareholders of record at the close of business on March 23, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto…

Results of Operations and Financial Condition. On February 12, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated…

Results of Operations and Financial Condition. On January 12, 2026, during its scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter ended December 31, 2025 is between $965 million and $970 million and that fourth quarter 2025 Bruker Scientific Instruments segments book-to-bill ratio was above 1.0. The Company also provided a preliminary outlook for the…

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this Current Report on Form 8-K that do not describe historical facts may con…

Director — Jack J. Phillips: The filing discloses the appointment of a new director to a newly created seat, which is a routine board expansion rather than a departure of a senior executive.

Results of Operations and Financial Condition. On November 3, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by re…

Material Modification of Rights of Security Holders. On September 8, 2025, Bruker Corporation (the “Company”) issued 2,760,000 shares, or $690,000,000 aggregate liquidation preference, of its 6.375% Mandatory Convertible Preferred Stock, Series A (the “Mandatory Convertible Preferred Stock”) (including 360,000 shares, or $90,000,000 aggregate liquidation preference, of Mandatory Convertible Preferred Stock issued upon exercise by the underwriters of over-allotment option in full) pursuant to…

Results of Operations and Financial Condition. On August 4, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference…

Results of Operations and Financial Condition. On July 21, 2025, Bruker Corporation (the “Company”) issued a press release announcing unaudited preliminary results for the second quarter of 2025. A copy of the press release is attached hereto as Exhibit 99.1. The financial results referred to in the press release are unaudited and preliminary estimates that (i) represent the most current information available to management as of the date of this Current Report on Form 8-K, (ii) are subject to…

The filing discloses the approval of a new incentive compensation plan, which is a routine corporate governance matter rather than a change in management personnel.

Other Events On May 14, 2025, Bruker Corporation (the “Company”) issued a press release regarding a settlement reached with 10x Genomix, Inc. on a previously disclosed litigation matter. A copy of the press release is attached hereto as Exhibit 99.1. Section 9 – Financial Statements and Exhibits

Results of Operations and Financial Condition. On May 7, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…

Results of Operations and Financial Condition. On April 11, 2025, Bruker Corporation (the “Company”) issued a press release announcing unaudited preliminary revenue for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The financial results referred to in the press release are unaudited and preliminary estimates that (i) represent the most current information available to management as of the date of this Current Report on Form 8-K, (ii) ar…

Director — Laura Francis: The filing discloses the appointment of a new director to a newly created seat, which is a routine board expansion rather than a departure of an existing executive.

Results of Operations and Financial Condition. On February 13, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three months and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by re…

Chief Accounting Officer — Thomas Bures: The filing discloses the appointment of an external candidate as Chief Accounting Officer, which is a new hire rather than a departure.